Abstract
No translate
No translate
No translate
No translate
Vũ Mạnh Cường; Phạm Thái Sơn; Vũ Anh Dũng
Home
NGHIÊN CỨU LÂM SÀNG
Issue: Số 96 , 2021
BỆNH VAN TIM
No translate
Lê Thị Hoa: Bác sĩ nội trú, Đại học Y Hà Nội;
Phạm Thái Sơn: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Đỗ Doãn Lợi: Bộ môn Tim mạch - Trường Đại học Y Hà Nội;
Kim Ngọc Thanh: Viện Tim mạch Việt Nam - Bệnh viện Bạch Ma;
Lê Thanh Tùng: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Trương Thanh Hương: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
References
1.
1. TrailokyaA,HiremathJS,SawhneyJ,etal. Acenocoumarol: A Review of Anticoagulant Efficacy and Safety. The Journal of the Association of Physicians of India. Feb 2016;64(2):88-93.
2.
2. Buzoianu AD, Militaru FC, Vesa SC, Trifa AP, Crişan S. The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population. Blood cells, molecules & diseases. Mar 2013;50(3):166-70. doi:10.1016/j.bcmd.2012.10.010.
3.
3. WadeliusM,PirmohamedM. Pharmacogenetics of warfarin: current status and future challenges. Thepharmacogenomics journal. Apr 2007;7(2):99-111. doi:10.1038/sj.tpj.6500417.
4.
4. Hylek EM. Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors. Seminars in vascular medicine. Aug 2003;3(3):271-8. doi:10.1055/s-2003-44463.
5.
5. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Jama. Apr 3 2002;287(13):1690-8. doi:10.1001/ jama.287.13.1690.
6.
6. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. The New England journal of medicine. Jun 2 2005;352(22):2285-93. doi:10.1056/ NEJMoa044503.
7.
7. ShawK,AmstutzU,KimRB,etal. Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. Ther Drug Monit. Aug 2015;37(4):428-36. doi:10.1097/ ftd.0000000000000192.
8.
8. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Annals of internal medicine. Apr 1 1993;118(7):511-20. doi:10.7326/0003-4819-118-7-199304010-00005.
9.
9. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. The American journal of medicine. Sep 1993;95(3):315-28. doi:10.1016/0002- 9343(93)90285-w.
10.
10. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thrombosis and haemostasis. Jan 2004;91(1): 87-94. doi:10.1160/th03-06-0379.
11.
11. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. Jan 22 2009;113(4):784-92. doi:10.1182/blood-2008-04-149070
12.
12. Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data. New England Journal of Medicine. 2009;360(8):753-764. doi:10.1056/NEJMoa0809329.
13.
13. Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clinical pharmacology and therapeutics. Sep 2017;102(3):397-404. doi:10.1002/cpt.668.
14.
14. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clinical pharmacology and therapeutics. Sep 2008;84(3):326-31. doi:10.1038/ clpt.2008.10.
15.
15. JonasDE,EvansJP,McLeodHL, et al. Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. Pharmacogenomics. Oct 2013;14(13):1593-603. doi:10.2217/pgs.13.145.
Files
Article Views422
Document Views1
Downloads5
Section
NGHIÊN CỨU LÂM SÀNG
Issue
Số 96 , 2021
Category
BỆNH VAN TIM
Pages
63-70
Copyright Holder
2021 Tạp chí Tim mạch học Việt Nam